Skip to main content
SpringerLink
Log in

Thromboembolism and Janus Kinase Inhibitors

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vallejo-Yagüe E, Weiler S, Micheroli R, Burden AM. Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of WHO VigiBase. Drug Saf. 2020. https://doi.org/10.1007/s40264-020-00958-9.

    Article  PubMed  Google Scholar 

  2. Scott IC, Hider SL, Scott DL. Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf. 2018;41:645–53.

    Article  CAS  Google Scholar 

  3. Verden A, Dimbil M, Kyle R, Overstreet B, Hoffman KB. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41:357–61.

    Article  CAS  Google Scholar 

  4. Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study. Arthritis Rheumatol. 2019;71:892–900.

    Article  CAS  Google Scholar 

  5. Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554–733.

    Article  CAS  Google Scholar 

  6. https://clinicaltrials.gov/ct2/show/NCT02092467. Assessed 15 June 2020.

  7. https://www.gov.uk/drug-safety-update/tofacitinib-xeljanz-restriction-of-10-mg-twice-daily-dose-in-patients-at-high-risk-of-pulmonary-embolism-while-safety-review-is-ongoing. Assessed 15 June 2020.

  8. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843–7.

    Article  CAS  Google Scholar 

  9. Reed GW, Gerber RA, Shan Y, et al. Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. Rheumatol Ther. 2019;6:573–86.

    Article  Google Scholar 

  10. Bird P, Littlejohn G, Butcher B, et al. Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05021-7.

    Article  PubMed  Google Scholar 

  11. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thromb. 2016;41:3–14.

    Article  CAS  Google Scholar 

  12. Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015;128(539):e7–539.e17.

    Google Scholar 

  13. Li LY, Lu N, Lacaille D, Xie H, Esdaile J, Avina-Zubieta JA. Risk of venous thromboembolism in rheumatoid arthritis patients initiating biologic and non-biologic DMARDs, a population-based study. Arthritis Rheumatol. 2019;71(Suppl 10):1894.

    Google Scholar 

  14. Cohen S, Curtis JR, DeMasi R, et al. Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Ther. 2018;5:283–91.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, Cutcombe Road, London, SE5 9RJ, UK

    Fowzia Ibrahim & David L. Scott

Authors
  1. Fowzia Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David L. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David L. Scott.

Ethics declarations

Author Contributions

Both authors contributed equally to this commentary.

Funding

No funding was received for this commentary.

Conflict of interest

Fowzia Ibrahim and David L. Scott declare that they have no conflict of interest.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Additional information

This comment refers to the article available online at https://doi.org/10.1007/s40264-020-00958-9.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ibrahim, F., Scott, D.L. Thromboembolism and Janus Kinase Inhibitors. Drug Saf 43, 831–833 (2020). https://doi.org/10.1007/s40264-020-00973-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-020-00973-w

Search

Navigation